Takeda Signs an Exclusive Multi-Target Research Agreement with Sosei Heptares to Develop and Commercialize Therapies Modulating GPCR

 Takeda Signs an Exclusive Multi-Target Research Agreement with Sosei Heptares to Develop and Commercialize Therapies Modulating GPCR

Shots:

  • Sosei Heptares to receive $26M up front, R&D funding, $1.2B+ development & commercial milestones and royalties on sales of the licensed products. Takeda to get WW rights to develop & commercialize therapies for each target through specified pharmacological approaches in the collaboration
  • The focus of the agreement is to develop multiple GPCR targets nominated by Takeda by combining Sosei Heptares’ GPCR-focused structure-based drug design capabilities with Takeda’s expertise in discovery, development and therapeutic area
  • The partners initially work on GI targets to discover therapies for gut inflammation and motility disorders with an expected expansion of an agreement in other therapeutic areas

Click here to­ read full press release/ article | Ref: Sosei Heptares | Image: The Boston Globe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post